Dr. Moo Rim Kang received his Ph.D. in Pharmacy from Chungnam National University, Korea in 2008. In August 2010, he joined the Li lab at the University of California, San Francisco (UCSF) as a postdoctoral fellow. His postdoctoral work involves the anti-tumor effect of NKX3-1 activation by RNAa (RNA activation) and small activating dsRNA-based therapeutics targeting CDKN1A for the treatment of bladder cancer. Dr. Kang is a well-trained research scientist specialized in cancer biology and focused on evaluation of drug candidates not only small molecules but also small nucleic acids including saRNA. He has extensive experience with in vivo studies such as human tumor xenografts, live surgery and immunohistochemistry and has strong technical skills in molecular/cellular biology. He has authored and co-authored over 30 peer-reviewed articles. Dr. Kang joined Ractigen Therapeutics in December 2016. Prior to that, he was the team leader in degenerative arthritis research company (Garam E&C) in Korea.